@Article{biocell.2019.04763,
AUTHOR = {Wen LI, Junli YANG, Dong ZHOU, Jinghui ZHANG, Qingcui ZHUO},
TITLE = {Meta-analysis evaluation of the treatment of neonatal hypoxic– ischemic encephalopathy with ganglioside},
JOURNAL = {BIOCELL},
VOLUME = {43},
YEAR = {2019},
NUMBER = {1},
PAGES = {7--12},
URL = {http://www.techscience.com/biocell/v43n1/33352},
ISSN = {1667-5746},
ABSTRACT = {The efficacy and safety of ganglioside in the treatment of neonates who suffer from hypoxic–ischemic
encephalopathy (HIE) needs to be fully evaluated. We searched the following databases: PubMed, ScienceDirect,
LISTA, CNKI, Chinese biomedical literature database and Wanfang digital journals of full-text database to determine
the inclusion and exclusion criteria of papers and a total of 12 papers were included after quality evaluation. Then we
conducted the meta-analysis with RevMan5.0 software. The results showed that compared with the control group, the
abnormal rate declined in the ganglioside-treated group (relative risk (RR)=0.27, 95% confidence interval (CI)= 0.05–
1.96). NBNA records of the 7, 10–14d neonates were improved effectively: RR (95% CI) were 2.28 (0.86–3.42) and 2.53
(1.04–2.92) respectively. Neural system sequelae incidence was reduced significantly: RR (95% CI) = 0.35: (0.15–0.79).
Ganglioside treatment could effectively reduce the abnormality rate of head size, improve the neurological score, reduce
the incidence of neurological sequelae, and significantly prompt clinical recovery for neonates with HIE.},
DOI = {10.32604/biocell.2019.04763}
}